AVEO Pharmaceuticals Inc.'s golden touch remained intact as the Cambridge, Mass.-based company grossed $100 million plus in an underwritten public offering of 5.75 million shares of common stock at $17.50 a share, a discount of about 8 percent. An underwriters' option could add as much as $15 million more.